Anavex Life Sciences Corp (AVXL)

[sokol]

It seems that even without Anavex obtaining a patent on the combination of AVXL 2-73 and donepezil (if AVXL is approved by the FDA), AVXL 2-73 may be prescribed as an add on therapy to donepezil. Of course, it is much more valuable for Anavex though to have a patent on the combination of 2-73 and donepezil to be administered in one pill rather than the two drugs to be taken separately. These are some reasons, I think:

1. Patient compliance, although CBD points out that this may not be a big deal. It's easier to administer one pill than 2. Dosage is more likely to be correct, etc. Plus, patients may forget to take one pill or take more than one when they should take only one of each.
2. Patent life (monopoly) may be extended as IP points out.
3. Another company may apply for some other combinations of AD drugs, and multiple patents by Anavex may block them if combination patents, methods of use patents are obtained by Anavex.(a patent person may better address this).
4. Its always better to have multiple patents to enforce. If enforcement fails on one, one of the others may succeed.